<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220423054620N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-06-08</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of high-power and low-power laser and drug therapy in improving the symptoms, function and sonographic findings in patients with  carpal tunnel syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the comparative effect of high-power and low-power laser and drug therapy in improving the symptoms, function and sonographic findings in patients with mild to moderate carpal tunnel syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>66</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/63647</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, 66 eligible patients are randomly selected. For this, the letter A is written on 22 sheets, the letter B is written on 22 sheets, and the letter C is written on 22sheets, and each of them is placed in an envelope. Each patient is then asked to choose one of the envelopes. Depending on the selected envelope, the patient is assigned to one of three groups, Blinding description: In this study, all three groups will be prescribed drug treatment, and in addition, two groups will be under low-power or high-power laser. Due to the difference in the laser power intensity, the Care provider is aware of the type of intervention in each group, but the patient will not be aware of the laser power used. In addition, the investigator, outcome assessor, and data analyzer will not know the type of intervention in the three groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Carpal tunnel syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Control group: In this group, patients have routinely prescribed wrist splints, in addition to vitamin B1 and gabapentin 100 mg for two weeks. Intervention 2: Intervention group 1: In this group, patients are prescribed routine treatment including a wrist splint, vitamin B1, and gabapentin 100 mg for two weeks. In addition, patients are treated with a low-power laser (New Vision device) five days a week (for two weeks) with a wavelength of 808 nm and a frequency of 1000 Hz, and an energy of 4  J/cm2 five days a week (for two weeks). The device is placed on the pulse settings and in the area of the carpal tunnel and the palm area in the path of the median nerve branches, the median nerve of fingers 1, 2, 3, and 4 will be fast manual scanning. Intervention 3: Intervention group 2: In this group, patients are prescribed routine treatment including wrist splint, vitamin B1 and gabapentin 100 mg for two weeks. In addition, patients are treated with a high-power laser (Fisioline device) five days a week (for two weeks) with a wavelength of 1064-910 nm and a frequency of 1000 Hz and an energy of 4 J/cm2. The device is placed on the pulse settings and in the area of the carpal tunnel and the palm area in the path of the median nerve branches, the median nerve of fingers 1, 2, 3 and 4 will be fast manual scanning.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Raziye Maghroori</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Physical Medicine and Rehabilitation Department, Kashani Hospital, Kashani Street.</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8183983434</zip>
        <telephone>+98 31 3233 0091</telephone>
        <email>maghroori@mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Raziye Maghroori</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Physical Medicine and Rehabilitation Department, Kashani Hospital, Kashani Street.</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8183983434</zip>
        <telephone>+98 31 3233 0091</telephone>
        <email>maghroori@mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with mild to moderate carpal tunnel syndrome
Age category over 18 years
No history of injection in the carpal tunnel in a recent month
Consent to participate in the study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Having neuropathic diseases
Having systemic diseases that affect treatment (such as hypothyroidism, diabetes, rheumatism)
Having a history of carpal tunnel surgery
Pregnancy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G56.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Carpal tunnel syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: In this group, patients have routinely prescribed wrist splints, in addition to vitamin B1 and gabapentin 100 mg for two weeks.</i_keyword>
      <i_keyword>Intervention group 1: In this group, patients are prescribed routine treatment including a wrist splint, vitamin B1, and gabapentin 100 mg for two weeks. In addition, patients are treated with a low-power laser (New Vision device) five days a week (for two weeks) with a wavelength of 808 nm and a frequency of 1000 Hz, and an energy of 4  J/cm2 five days a week (for two weeks). The device is placed on the pulse settings and in the area of the carpal tunnel and the palm area in the path of the median nerve branches, the median nerve of fingers 1, 2, 3, and 4 will be fast manual scanning.</i_keyword>
      <i_keyword>Intervention group 2: In this group, patients are prescribed routine treatment including wrist splint, vitamin B1 and gabapentin 100 mg for two weeks. In addition, patients are treated with a high-power laser (Fisioline device) five days a week (for two weeks) with a wavelength of 1064-910 nm and a frequency of 1000 Hz and an energy of 4 J/cm2. The device is placed on the pulse settings and in the area of the carpal tunnel and the palm area in the path of the median nerve branches, the median nerve of fingers 1, 2, 3 and 4 will be fast manual scanning.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Symptoms. Timepoint: Before treatment, one month and three months after treatment. Method of measurement: Boston Questionnaire.</prim_outcome>
      <prim_outcome>Functional status. Timepoint: Before treatment, one month and three months after treatment. Method of measurement: Boston Questionnaire.</prim_outcome>
      <prim_outcome>Pain. Timepoint: Before treatment, one month and three months after treatment. Method of measurement: Visual Analog Scale (VAS).</prim_outcome>
      <prim_outcome>Nerve Conduction Velocity (NCV) across wrist. Timepoint: Before treatment and three months after treatment. Method of measurement: Nerve and muscle strip.</prim_outcome>
      <prim_outcome>Sensory nerve action potential (SNAP) across wrist. Timepoint: Before treatment and three months after treatment. Method of measurement: Nerve and muscle strip.</prim_outcome>
      <prim_outcome>Compound Muscle Action Potential (CMAP) across wrist. Timepoint: Before treatment and three months after treatment. Method of measurement: Nerve and muscle strip.</prim_outcome>
      <prim_outcome>Cross-sectional area (CSA) carpal tunnel. Timepoint: Before treatment and three months after treatment. Method of measurement: Sonography.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Isfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-02-13</approval_date>
        <contact_name>Ethics committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Street address Isfahan University of Medical Sciences, Hezar Jarib Ave., Azadi Sq Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
